Editos Medicine is a privately-owned limited liability company operating within the construction industry, specializing in the development and commercialization of gene editing therapies. Founded as a leading entity in the field, Editas focuses exclusively on advancing treatments for debilitating conditions affecting human health. The company’s core business involves researching, developing, manufacturing, and licensing CRISPR technology to address genetic diseases such as sickle cell anemia, beta-thalassemia, and muscular dystrophies. Based at 184a Kingston Road in Epsom, Surrey, UK (KT19 0SF), Editos Medicine is a registered with the Securities and Exchange Commission (SEC) under regulatory number 13334193. The company’s SIC codes encompass construction of domestic buildings, indicating its operational activities within this sector. Editos Medicine operates as a contractor for skilled workers, demonstrating a commitment to employing individuals in a specialized field. The company is actively seeking international partnerships and collaborations to accelerate the translation of its research into viable therapies. Editas Medicine’s strategic focus centers on securing intellectual property rights and establishing robust clinical trial pathways. The company maintains a relatively small workforce, reflecting its dedicated research and development efforts within the gene editing space.

Editos Medicine is a privately-owned limited liability company operating within the construction industry, specializing in the development and commercialization of gene editing therapies. Founded as a leading entity in the field, Editas focuses exclusively on advancing treatments for debilitating conditions affecting human health. The company’s core business involves researching, developing, manufacturing, and licensing CRISPR technology to address genetic diseases such as sickle cell anemia, beta-thalassemia, and muscular dystrophies. Based at 184a Kingston Road in Epsom, Surrey, UK (KT19 0SF), Editos Medicine is a registered with the Securities and Exchange Commission (SEC) under regulatory number 13334193. The company’s SIC codes encompass construction of domestic buildings, indicating its operational activities within this sector. Editos Medicine operates as a contractor for skilled workers, demonstrating a commitment to employing individuals in a specialized field. The company is actively seeking international partnerships and collaborations to accelerate the translation of its research into viable therapies. Editas Medicine’s strategic focus centers on securing intellectual property rights and establishing robust clinical trial pathways. The company maintains a relatively small workforce, reflecting its dedicated research and development efforts within the gene editing space.